WO2005102369A1 - 細菌細胞壁骨格成分を含有する製剤 - Google Patents
細菌細胞壁骨格成分を含有する製剤 Download PDFInfo
- Publication number
- WO2005102369A1 WO2005102369A1 PCT/JP2005/007523 JP2005007523W WO2005102369A1 WO 2005102369 A1 WO2005102369 A1 WO 2005102369A1 JP 2005007523 W JP2005007523 W JP 2005007523W WO 2005102369 A1 WO2005102369 A1 WO 2005102369A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- water emulsion
- cell wall
- freeze
- bacterial cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention has a stable bacterial cell wall skeleton component [hereinafter referred to as bacteria CWS.
- bacteria CWS a stable bacterial cell wall skeleton component
- the present invention relates to a pharmaceutical composition containing a cell wall skeleton component (Cell Wall Skeleton) as an active ingredient in some cases, specifically a freeze-dried preparation.
- Cell Wall Skeleton a cell wall skeleton component
- Bacterial cell wall skeletal components have an immunostimulatory effect, and are known to exhibit antitumor activity in, for example, experimental tumor systems using animal models and human cancer immunotherapy. Further, it is known that when the above bacterial cell wall skeleton component is dispersed and emulsified in an oil component and administered as an oil-in-water emulsion formulation, the antitumor effect due to the immunostimulatory action is remarkably enhanced.
- BCG-CWS Bacille Calmette-Guerin
- the oil-in-water emulsion preparation can be prepared by adding emulsion containing water to a paste-like composition in which bacteria-CWS is dispersed in oil (Non-patent Document 3). , 4 and 5).
- Oil-in-water emulsion formulations containing bacteria-CWS are unstable, and currently, in clinical settings, a small amount of oil-in-water emulsion formulations are prepared at the time of use.
- Bacteria To supply lyophilized preparations containing CWS as pharmaceuticals, (1) have the long-term storage stability required for pharmaceuticals, and (2) use lyophilized preparations such as distilled water for injection. Emulsion power obtained by adding a dispersion solvent It is important that it is substantially equivalent to oil-in-water emulsion before lyophilization. However, the freeze-dried preparations known so far have problems such as a phenomenon that the content of bacterial CWS, which is an active ingredient, decreases under severe conditions such as high temperature.
- antioxidants such as tocopherol are widely used for the purpose of stabilizing pharmaceuticals containing substances susceptible to oxidation and cosmetic liquids.
- Patent Document 1 International Publication Pamphlet No. 00Z3724
- Patent Document 2 International Publication Pamphlet No. 2004Z012751
- Non-Patent Document 1 A. Hayashi et al., Pro. Japan Acad., 70, Ser. B 205-209 (1994)
- Non-Patent Document 2 A. Hayashi et al., Pro. Japan Acad., 74, Ser B 20550-55 (1998)
- Non-Patent Document 3 J. Nat. Cancer Inst. 48, 831-835 (1972)
- Non-Patent Document 4 J. Bacteriol, 92,869-879 (1966)
- Non-Patent Document 5 Gann, 69, 619-626 (1978)
- the problem to be solved by the present invention is to provide a pharmaceutical composition containing a bacterial cell wall skeleton component as an active ingredient, which shows excellent storage stability, specifically a freeze-dried preparation.
- the present inventors have intensively studied to develop a freeze-dried preparation containing bacterial CWS and oil as a pharmaceutical product!
- the lyophilized preparation can be prepared using the methods described in Patent Documents 1 and 2 described above. That is, (1) A mixed oily substance with oils such as bacteria-CWS and squalene is prepared using an organic solvent, (2) polysorbates are added as a surfactant, and (3) mannitol as an excipient. (4) (3) is emulsified in water. Therefore, an oil-in-water emulsion with high uniformity can be produced, and a freeze-dried preparation can be obtained by freeze-drying the oil-in-water emulsion.
- the present inventors have found that the stability of a lyophilized preparation containing bacterial CWS is remarkably improved by adding an antioxidant. Furthermore, when preparing an oil-in-water emulsion as an intermediate, a buffer is added, and the pH of the solution in the emulsion is adjusted to pH 5.5 to 8.5, thereby stabilizing the stability of the lyophilized formulation. Has been found to improve synergistically. That is, it has been found that long-term storage stability of a lyophilized preparation is dramatically improved by adding an antioxidant, preferably by adding a buffering agent.
- the present invention has been completed based on the above findings.
- Surfactant The freeze-dried preparation according to [1], wherein the agent is a polyoxyethylene sorbitan fatty acid ester;
- the amount of released mycolic acid is within about 2%
- the concentration of the bacterial cell wall skeletal component obtained by condensing the freeze-dried preparation with water is 0.5 mgZml to l mg / ml.
- H value is substantially equivalent to pH before storage;
- the concentration of the bacterial cell wall skeletal component is 0.5 mgZml to 1 mg / ml.
- the oil-in-water emulsion before lyophilization and the bacterial cell wall skeletal component obtained by condensing the lyophilized preparation with water.
- a buffering agent is blended to adjust the pH power of the oil-in-water emulsion having a concentration of 0.5 mgZml to l mg / ml to 5.5 to 8.5.
- the invention's effect [0008] According to the present invention, it has become possible to provide a freeze-dried preparation having excellent long-term storage stability and containing bacterial CWS as an active ingredient.
- the lyophilized preparation is useful as a cancer immunotherapeutic agent.
- bacterial cell wall skeleton component refers to any bacterium containing a cell wall skeleton component (Cell Wall Skeleton; CWS) derived from a microorganism. It represents a body-derived component, and is a concept that includes both microbial cells themselves, such as killed Mycobacterium tuberculosis, and cell wall skeleton components isolated to some extent.
- CWS cell Wall Skeleton
- Examples of microorganisms derived from CWS include Gram-positive bacilli, Mycobacterium bacteria, Nocardia bacteria, Corynebacterium bacteria, Rhodococcus bacteria, and Gordona bacteria.
- Mycobacteria bacterium refers to a mycobacterial bacterium belonging to the genus Mycobacterium, specifically Mycobacterium tuberculosis of Mycobacterium tuberculosis, Mycobacterium bovis [Mycobacterium tuberculosis, BCG ( Canolemet 'Guerin; including Bacille Calmette- Guerin)], Mycobacterium africanum (African), Mycobacterium microti (N.
- Mycobacterium leprae Rostibacterium
- non-tuberculous antiacid Mycobacterium kansasu is a bacterial group
- Mycobacterium avium ⁇ Mycobacterium phlei Hitoshiryoku 21 Agerire preferred are BCG bacterium which is a kind of Mycobacterium genus Mycobacterium tuberculosis and Nocardia rubra which is a kind of Nocardia group bacteria.
- CWS Cell wall skeletal component
- the concentration of bacteria CWS contained in the oil-in-water emulsion is used so as to be 0.01 to 10 mg / ml as emulsion.
- it is 0.1 mg / ml to 2 mg / ml, more preferably 0.2 mg / ml to lmg / ml, and still more preferably 0.5 mg / ml to lmg / ml.
- the "oil” of the present invention includes mineral oils and animal and vegetable oils as described in Immunology Article 27, 311 to 329 (1974).
- mineral oil for example, fluidized baraf In (Drecall 6VR, Moresco Bioless U-6, Moresco Bioless U-8, etc.), Biol (Bayol F), etc.
- vegetable oils include soybean oil, synthelan 4, ethyl oleate, peanut oil, coconut oil, sesame oil, AD-65 (a mixture of peanut oil, aracelle, and aluminum monostearate).
- animal oils include terpenoid derivatives such as squalene and squalene.
- oils selected from among these animal and vegetable oils and mineral oils.
- squalene or a mixture of squalene and vegetable oils (or oils derived from them) such as soybean oil, ethyl oleate or oleic acid, and mineral oils such as Drecor 6VR, various liquid paraffins, etc.
- Drecor 6VR various liquid paraffins, etc.
- squalene, Drecol 6VR, a mixture of squalene and soybean oil, a mixture of squalene and ethyl oleate, or a mixture of squalene and Drecol 6VR can be mentioned. Even more preferably, squalene is used.
- the oil concentration is such that the viscosity of the paste of bacteria CWS and oil (mixed oil) described below is about 0.7 poise (25 ° C) or less, preferably about 0.2 to about 0.6 poise (25 ° C), more preferably about 0.28. It is adjusted as appropriate so that it becomes ⁇ 0.55 poise (25 ° C.).
- each oil can be mixed at an appropriate composition ratio, but the viscosity when mixed with bacterial CWS is about 0.2 to 0.7 poise (25 ° C)
- the composition ratio is as follows.
- a paste containing about 0.35 to 0.55 poise (25 ° C), more preferably about 0.39 to 0.51 0 136 (bacterial paste having a viscosity of 25 ° is suitable.
- about 0.66 g of bacterial CWS, about 6.6 to 35.2 g, preferably about 8.4 to 35.2 g of squalene can be mentioned.
- the above paste has the following 1) and 2):
- Organic solvent examples include hydrocarbon solvents such as heptane and toluene, hydrocarbon solvents such as heptane containing alcohol solvents such as 5 to 20% ethanol, 1,2-dichloroethane, and black mouth. And halogen-based hydrocarbon solvents such as form.
- Preparation method of the paste and organic used in the step (1) Regarding the solvent International Publication Pamphlet No. 2004/012751 can be referred to.
- the "surfactant” that can be used in the present invention is not particularly limited as long as it is a surfactant used in pharmaceutical preparations.
- examples thereof include phospholipids and nonionic surfactants.
- phospholipids include phosphatidylamine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, sphingomyelin, and lecithin. Hydrogenated phospholipids can also be used.
- Nonionic surfactants include polyoxyethylene polyoxypropylene copolymers, polyoxyethylene hydrogenated castor oil derivatives, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, and the like. It is done.
- the polyoxyethylene sorbitan fatty acid ester includes polyoxyethylene sorbitan monolaurate (polysorbate 20), monopalmitate (polysorbate 40), monostearate (polysorbate 60), or monooleate (polysorbate 80).
- Examples of sorbitan fatty acid esters include sorbitan monolaurate (Span20), mononolemate (Span40), monostearate (Span60), monooleate (Span80), and the like.
- Preferred surfactants include egg yolk phosphatidylcholine, egg yolk lecithin, soybean lecithin, polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 60 (HC 0-60), polyoxyethylene hydrogenated castor oil 50 (HCO-50), Mention may be made of polyoxyethylene (160) polyoxypropylene (30) glycol (pull nick F68). More preferred are polyoxyethylene sorbitan fatty acid esters (polysorbates) such as polysorbate 80, polysorbate 40, polysorbate 60, etc., and particularly preferred surfactants include polysorbate 80.
- the concentration of the surfactant is suitably in the range of 0.01 to 10% w / w, preferably 0.01 to 3% w / w, more preferably 0.05% to l% w / w. .
- surfactants are not limited to one type, and can be used in combination of several types as appropriate.
- the “antioxidant” means a radical inhibitory function that suppresses a chain reaction of auto-oxidation or a peroxide decomposition function that deactivates peroxides by non-radical decomposition. If it is an antioxidant that can be used in pharmaceutical preparations, it is particularly limited. There is no. Specifically, tocopherols, butylhydroxytoluene (hereinafter referred to as BHT), butylhydroxydiamine (hereinafter referred to as BHA), nordihydroguaiaretin, propyl gallate, fatty acid ester of vitamin C or sorbic acid Etc. can be illustrated. Preferred examples of the antioxidant include tocopherols.
- tocopherols examples include ⁇ -tocopherol, j8-tocopherol, ⁇ -tocopherol, ⁇ tocopherol, or a mixture of these two to four types of tocopherol. It can be illustrated. Specific examples include ⁇ -tocopherol (trade name: ⁇ Mitsutus 80, ⁇ mix 70L, etc.).
- the amount of these antioxidants in the present invention is preferably 0.0001% by weight or more based on the total composition in order to sufficiently prevent oxidative degradation of the drug substance. More preferably 001% by weight or more.
- the upper limit of blending is not particularly limited, but it is generally blended within a range of 10.0% by weight or less based on the entire composition.
- the concentration of the antioxidant is preferably in the range of 0.0001% to 10% w / w in the oil-in-water emulsion, more preferably 0.0001% to 5% w / w.
- the antioxidant is not limited to one type, and may be used in combination of several types as appropriate.
- Antioxidants may be added at any stage in the production process of oil-in-water emulsions.
- a mixed oil (paste) of bacteria—CWS and oil it can be dissolved in
- excipient is a component used for the purpose of maintaining / improving the stability of the above emulsion as an emulsion or the stability of a freeze-dried product.
- excipients that can be used in the present invention include monosaccharides, sugar alcohols, polysaccharides, amino acids, proteins, ureas, and inorganic salts.
- monosaccharides and disaccharides include glucose, fructose, sucrose, ratatose, and trehalose.
- sugar alcohols include mannitol and sorbitol.
- Preferred examples of the polysaccharide include dextran, starch, maltodextrin, cellulose, polybutyropyrrolidone, and sodium alginate.
- amino acids neutral amino acids such as alanine, glycine, proline and the like are preferred, and glycine can be mentioned as a more preferred neutral amino acid.
- preferred proteins include albumin, gelatin, and collagen. It is done.
- inorganic salts include sodium chloride, potassium salt, calcium salt, sodium sulfate, sodium carbonate and the like.
- Preferred excipients include monosaccharides or sugar alcohols, and particularly preferred excipients include mannitol.
- excipients are not limited to one type, and may be used in combination of several types as appropriate.
- the concentration of the excipient is suitably in the range of 0.1% to 20% w / w in the oil-in-water emulsion, preferably 0.1 to 10% w / w.
- the suitable concentration of the excipient varies depending on the type of the excipient, but can be appropriately adjusted according to the production scale and the content of each component.
- amino acids such as glycine
- it is 2.25% (300 mM) to 11.25% (1500 mM), preferably about 6.75% (900 mM).
- the concentration in the oil-in-water emulsion is preferably 1 to 10%, more preferably 1 to 8%, more preferably about 3 to 6%.
- the substances mentioned as the excipient may be used as an isotonic agent as necessary. These excipients or tonicity agents are not limited to one type, and several types can be used in combination as appropriate. Usually, the excipient also serves as a tonicity agent, but a substance different from the excipient may be selected as the tonicity agent.
- the concentration of the tonicity agent is appropriately set according to the content of other components, but is usually in the range of 0.1% to 30% W / W, preferably 1% to 10% W / W. is there.
- buffering agent in the present specification include glycine, alanine, arginine, glutamine, cysteine, serine, threonine, Norin, histidine, ferrolanine, methionine, aspartic acid, glutamic acid, and ⁇ -aminocaproic acid.
- Amino acids such as lysine and leucine or their hydrochlorides, salts such as sodium and potassium salts, ampholytes such as nicotinamide and aminobenzoic acid, or salts such as sodium salts thereof, citrate, phosphoric acid, lactic acid, Acetic acid, boric acid, propionic acid, butyric acid, valeric acid, glycolic acid, oxalic acid, malonic acid, succinic acid, dartaric acid, adipic acid, malic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phthalic acid , Sodium salts of weak acids such as tartaric acid, salts such as potassium salts, A combination of a salt and a strong acid such as a weak acid, hydrochloric acid or sulfuric acid, a Tris buffer, or the like can be given.
- mild phosphate buffer includes 5 mM to 50 mM sodium dihydrogen phosphate and disodium hydrogen phosphate, usually with a ratio of sodium dihydrogen phosphate and disodium hydrogen phosphate. It may be dissolved at 1: 2.3 (weight ratio), and the pH may be finely adjusted with an acid such as hydrochloric acid or a base such as sodium hydroxide or sodium hydroxide as appropriate.
- the Tris buffer include a buffer consisting of a 5 mM to 50 mM Tris solution, and the pH can be finely adjusted as appropriate with 0.1N to 4N hydrochloric acid or the like.
- citrate buffer solution examples include a buffer solution of 5 mM to 50 mM citrate solution, and the pH can be finely adjusted as appropriate with 0.1 N to 4 N hydrochloric acid or the like.
- a phosphate buffer is preferable.
- the blending amount of these buffering agents in the present invention is not particularly limited as long as it is sufficient to exhibit sufficient buffering capacity, but is preferably 5 to 20 mM, and more preferably 10 ⁇ 20mM.
- the amount of buffering agent is appropriately adjusted.
- the freeze-dried preparation of the present invention is excellent in long-term storage stability and has the following properties. That is,
- the amount of released mycolic acid is within about 2%
- the concentration of the bacterial cell wall skeletal component obtained by condensing the freeze-dried preparation with water is 0.5 mg / ml to lmg / ml.
- the pH value is substantially equivalent to the pH before storage.
- the free amount of mycolic acid is within about 1%.
- “substantially equivalent” means that the difference in pH of oil-in-water emulsion obtained by condensing a freeze-dried preparation before and after storage is within 0.8, preferably within 0.5. It represents that.
- An oil-in-water emulsion formulation can be provided by resuspending (condensing) the lyophilized formulation of the present invention with an aqueous solvent.
- the oil-in-water emulsion formulation is also included in the present invention.
- the aqueous solvent used to resuspend the lyophilized formulation in the present invention is This is a dispersion medium for the cation particles, and includes distilled water for injection, physiological saline, or buffer solution, but is not particularly limited as long as it is an injectable aqueous solvent.
- the aqueous solvent used to resuspend the freeze-dried preparation is an aqueous solvent containing an inorganic salt such as physiological saline or buffer
- the composition of the aqueous preparation is oil-in-water after resuspension. It may be appropriately selected in consideration of the stability of the type emulsion formulation.
- the concentration of the inorganic salt (inorganic salt added as a buffering agent excipient) in the oil-in-water emulsion formulation after resuspension is adjusted to be an isotonic solution when administered to humans. It is preferable.
- an oil-in-water emulsion containing bacteria—CWS, oil, surfactant and antioxidant which is a production intermediate for preparing the lyophilized preparation of the present invention, also falls within the scope of the present invention.
- the “oil-in-water emulsion” can further contain excipients, buffering agents and the like. That is, the oil-in-water emulsion preferably contains an excipient such as mannitol and is further adjusted to a pH of 5.5 to 8.5 by adding a buffer.
- the oil-in-water emulsion is obtained by the following production method described in the above-mentioned WO 2004Z012751 pamphlet. That is,
- the antioxidant can be combined in the above step 1) or 3), but is preferably added in the step 1).
- an excipient can be preferably blended.
- Examples of the organic solvent used above include toluene, heptane, heptane-ethanol mixed solvent, and the like. Methods for preparing bacterial CWS-containing pastes are described in WO OOZ3724 pamphlet and WO 2004Z012751 pamphlet.
- composition of the oil-in-water emulsion as the production intermediate and the oil-in-water emulsion obtained by condensing the freeze-dried preparation of the present invention includes the above-mentioned pace containing bacteria CWS. 0.1% to 20%, preferably 1% to 10% excipient, 0.01% to 10%, preferably 0.01% to 3% surfactant, 0.001% to 10%, preferably It contains 0.001% to 0.1% antioxidant.
- aqueous solvent examples include water, physiological saline, and a buffer solution.
- the “buffer” includes a buffer used for the purpose of keeping the pH of an oil-in-water emulsion formulation (including emulsion obtained by resuspending a freeze-dried formulation in water) constant. Represents an aqueous solution.
- the buffer that can be used in the present invention is not particularly limited, but is preferably a buffer used in pharmaceutical preparations.
- the oil-in-water emulsion formulation of the present invention is preferably adjusted to pH 5.5 to 8.5, preferably pH 6.0 to 7.0 with a buffer.
- a freeze-dried preparation can be produced by freeze-drying the aforementioned oil-in-water emulsion. That is, the freeze-dried preparation of the present invention can be obtained by freeze-drying an oil-in-water emulsion, and finally replacing the inside of the vial with nitrogen and capping.
- the freeze-drying temperature and time are not particularly limited. For example, the methods described in International Publication Pamphlet No. 00/3724, International Publication Pamphlet No. 2004/012751, etc. Can be mentioned.
- the oil-in-water emulsion formulation of the present invention is administered parenterally such as by injection.
- the dosage form varies depending on the therapeutic purpose and is not particularly limited. As a commonly used dosage form, for example, it can be administered as an injection from the skin.
- the amount of bacteria—CWS in the emulsion is usually 0.1-1.0 mg / ml, preferably 0.5-1.0 mg / ml.
- the lyophilized preparation of the present invention is resuspended in the oil-in-water emulsion of the present invention in an appropriate amount of an aqueous solvent such as water, physiological saline, or buffer solution.
- the concentration of each component in the oil-in-water emulsion when the lyophilized formulation is resuspended and administered to a living body may differ from the concentration of each component in the oil-in-water emulsion as a manufacturing intermediate before lyophilization. Good .
- the appropriate amount of the aqueous solvent is preferably in the range of 0.5 to 4 times the amount of liquid before lyophilization.
- the dose and frequency of administration vary depending on the target disease, patient symptoms, age, weight, sex, etc.For example, for adults, once a week or once every 4 weeks, 10 to 250 / A range of zg, preferably 25-200 ⁇ g, can be administered.
- the freeze-dried preparation and the oil-in-water emulsion preparation obtained by condensing the lyophilized preparation of the present invention are useful as cancer therapeutic agents or prophylactic agents, more specifically as immunotherapeutic agents.
- cancer therapeutic agents include lung cancer, stomach cancer, liver cancer, spleen cancer, colon cancer, uterine cancer, breast cancer, acute myeloid leukemia, tongue cancer, pharyngeal cancer, ovarian cancer, and brain tumor.
- the cancer therapeutic agent includes an embodiment as a cancer transition inhibitor.
- freeze-dried preparation of the present invention and the oil-in-water emulsion preparation obtained by condensing it can be used together with other immunotherapeutic agents, specifically cancer vaccines containing various cancer antigens as active ingredients.
- BCG—CWS 2770 mg was used as a cell wall skeleton component, and the mixture was added to a mixture of 70.4 g of mixture A and 400 mL of 10% ethanol Z90% heptane solution, and dispersed at room temperature by shaking or ultrasound. Thereafter, the mixture was heated to 70 ° C under a nitrogen or air stream to distill off ethanol Z heptane. Next, add 0.02 wZw% polysorbate 80ZlOmM phosphoric acid buffer 888.6g, and perform rough emulsification using a homomixer, and then add 36.7g of 10w Zw% polysorbate 80 aqueous solution. Went.
- BCG-CWS (1358 mg) was used as a cell wall skeletal component, added to a mixture of 35.2 g of mixture B and 200 mL of 10% ethanol Z90% heptane solution, and dispersed at room temperature by shaking or ultrasound. Thereafter, the mixture was heated to 70 ° C under a nitrogen or air stream to distill off ethanol Z heptane. Next, add 40.0 g of 0.02 wZw% polysorbate 80Zl0mM phosphoric acid buffer, perform rough emulsification using a homomixer, and further add 18.4 g of 10 w Zw% polysorbate 80 aqueous solution to perform main emulsification. It was.
- This oil-in-water emulsion formulation was dispensed into vials in 0.5 mL or 1 mL portions and lyophilized to obtain the lyophilized formulation of the present invention. Freeze-drying was performed using a freeze-dryer (DFM-05 A-S special, ULVAC).
- a freeze-dried preparation containing the antioxidant or buffer described in Examples 2, 5 and 6 and an antioxidant prepared by the method described in Example 14 of International Publication No. 2004/012751 The storage stability of no lyophilized formulation (Comparative Example 1) was evaluated. That is, each freeze-dried preparation was placed in a box and stored in a gas phase incubator maintained at 80 ° C. One week later, the preparation was taken out, and the amount of free mycolic acid and the pH after resuspension with distilled water for injection were measured.
- Example 4 As shown in Table 1, the formulation of Comparative Example 1 was stored at 80 ° C. for 1 week, and as a result, the amount of free mycolic acid significantly increased and the pH decreased significantly. On the other hand, in the freeze-dried preparations of Examples 5 and 6, it was found that both the amount of free mycolic acid and pH were suppressed. Further, the freeze-dried preparation of the present invention Examples 1 and 2 including both Kosani ⁇ agents and buffering agents, free Micaud Le acid content, the long-term storage stability Nag that vary little P H are both significantly improved I understand. (Here, the amount of free mycolic acid represents the ratio per total amount of BCG—CWS, and was measured using the method described in the pamphlet of International Publication No. 2004/012751.) Example 4
- a lyophilized preparation containing 5 mM, 10 mM, 20 mM, and lOO mM phosphate buffer was prepared in the same manner as in Example 1 (but not using tocopherol but using an ethanol heptane mixed solvent). The storage stability was tested in the same manner as in 3. The result of measuring the pH
- Table 3 shows the properties of the freeze-dried cake after storage for 1 week at 80 ° C.
- the numbers in the table indicate the number of bottles stored, and out of the 30 bottles, the number of vials that showed a change was emphasized.
- the freeze-dried preparations manufactured by lOOmM phosphate buffer, etc. are vials in which the properties of the freeze-dried cake after shrinkage storage (80 ° C for 1 week) float on the top of the bottle. Appeared. That is, the freeze-dried preparation prepared with a high-concentration phosphate buffer caused morphological changes under forced degradation storage conditions.
- shrink refers to a state in which the freeze-dried cake is shrunk, which is caused by melting a part of water in the frozen state during freeze-drying.
- a freeze-dried preparation was produced in the same manner as in Example 5 without adding tocofurol.
- the freeze-dried preparation containing the bacterial CWS of the present invention as an active ingredient is useful as a cancer immunotherapeutic agent having excellent long-term storage stability.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05734379A EP1741438A4 (en) | 2004-04-22 | 2005-04-20 | PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL |
US11/578,859 US20080032384A1 (en) | 2004-04-22 | 2005-04-20 | Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton |
CA002564180A CA2564180A1 (en) | 2004-04-22 | 2005-04-20 | Pharmaceutical preparation containing bacterial cell wall skeleton component |
JP2006512563A JP5041279B2 (ja) | 2004-04-22 | 2005-04-20 | 細菌細胞壁骨格成分を含有する製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-126827 | 2004-04-22 | ||
JP2004126827 | 2004-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005102369A1 true WO2005102369A1 (ja) | 2005-11-03 |
Family
ID=35196736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/007523 WO2005102369A1 (ja) | 2004-04-22 | 2005-04-20 | 細菌細胞壁骨格成分を含有する製剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080032384A1 (ja) |
EP (1) | EP1741438A4 (ja) |
JP (1) | JP5041279B2 (ja) |
CA (1) | CA2564180A1 (ja) |
WO (1) | WO2005102369A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015526463A (ja) * | 2012-08-23 | 2015-09-10 | アギラ・スペシャルティーズ・プライベート・リミテッド | 改善されたダプトマイシン注射用製剤 |
WO2018124132A1 (ja) * | 2016-12-26 | 2018-07-05 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2930443B1 (fr) * | 2008-04-29 | 2010-06-25 | Oreal | Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12 |
JO3190B1 (ar) * | 2011-10-19 | 2018-03-08 | Otsuka Pharma Co Ltd | محلول للتناول عن طريق الفم |
CA3026108A1 (en) | 2016-06-10 | 2017-12-14 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
CN111727235B (zh) * | 2019-01-15 | 2024-03-15 | 辽宁天安生物制药股份有限公司 | 赤红球菌产品及其制药用途 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02250835A (ja) * | 1989-02-04 | 1990-10-08 | Akzo Nv | ワクチン中のアジュバントとしてのトコール |
JPH09506887A (ja) * | 1993-12-23 | 1997-07-08 | スミスクライン・ビーチャム・バイオロジカルス (ソシエテ・アノニム) | ワクチン |
WO2000003724A1 (fr) * | 1998-07-16 | 2000-01-27 | Hayashi, Akira | Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif |
JP2001514208A (ja) * | 1997-09-05 | 2001-09-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
JP2001515870A (ja) * | 1997-09-05 | 2001-09-25 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
JP2002080364A (ja) * | 2000-09-01 | 2002-03-19 | Takeda Food Products Ltd | 免疫増強組成物 |
JP2002179577A (ja) * | 2000-12-12 | 2002-06-26 | Club Cosmetics Co Ltd | 抗腫瘍物質及び抗腫瘍剤 |
WO2003028758A1 (fr) * | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene |
WO2004012751A1 (ja) * | 2002-08-02 | 2004-02-12 | Sumitomo Pharmaceuticals Company, Limited | 細菌細胞壁骨格成分製剤 |
JP2004511529A (ja) * | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫刺激性オリゴヌクレオチドおよびトコールを含むアジュバント組成物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5428813A (en) * | 1977-08-09 | 1979-03-03 | Yuuichi Yamamura | Solid preparation containing cell membrane extract substance used as suspension when using same |
US4436728A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4505903A (en) * | 1982-06-30 | 1985-03-19 | Ribi Immunochem Research, Inc. | Pyridine soluble extract of a microorganism |
US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
JPH0278623A (ja) * | 1988-09-14 | 1990-03-19 | Sawai Seiyaku Kk | インターフェロン誘起剤 |
HU212924B (en) * | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
WO1993018150A1 (en) * | 1992-03-02 | 1993-09-16 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
US6303347B1 (en) * | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
JP4918188B2 (ja) * | 1997-12-16 | 2012-04-18 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | サブミクロンの水中油型エマルジョンと合わせた微粒子の使用 |
US6171590B1 (en) * | 1998-09-30 | 2001-01-09 | Corixa Corporation | Chemokine receptor peptide for inducing an immune response |
-
2005
- 2005-04-20 CA CA002564180A patent/CA2564180A1/en not_active Abandoned
- 2005-04-20 WO PCT/JP2005/007523 patent/WO2005102369A1/ja not_active Application Discontinuation
- 2005-04-20 JP JP2006512563A patent/JP5041279B2/ja not_active Expired - Fee Related
- 2005-04-20 EP EP05734379A patent/EP1741438A4/en not_active Withdrawn
- 2005-04-20 US US11/578,859 patent/US20080032384A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02250835A (ja) * | 1989-02-04 | 1990-10-08 | Akzo Nv | ワクチン中のアジュバントとしてのトコール |
JPH09506887A (ja) * | 1993-12-23 | 1997-07-08 | スミスクライン・ビーチャム・バイオロジカルス (ソシエテ・アノニム) | ワクチン |
JP2001514208A (ja) * | 1997-09-05 | 2001-09-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
JP2001515870A (ja) * | 1997-09-05 | 2001-09-25 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2000003724A1 (fr) * | 1998-07-16 | 2000-01-27 | Hayashi, Akira | Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif |
JP2002080364A (ja) * | 2000-09-01 | 2002-03-19 | Takeda Food Products Ltd | 免疫増強組成物 |
JP2004511529A (ja) * | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫刺激性オリゴヌクレオチドおよびトコールを含むアジュバント組成物 |
JP2002179577A (ja) * | 2000-12-12 | 2002-06-26 | Club Cosmetics Co Ltd | 抗腫瘍物質及び抗腫瘍剤 |
WO2003028758A1 (fr) * | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene |
WO2004012751A1 (ja) * | 2002-08-02 | 2004-02-12 | Sumitomo Pharmaceuticals Company, Limited | 細菌細胞壁骨格成分製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1741438A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015526463A (ja) * | 2012-08-23 | 2015-09-10 | アギラ・スペシャルティーズ・プライベート・リミテッド | 改善されたダプトマイシン注射用製剤 |
WO2018124132A1 (ja) * | 2016-12-26 | 2018-07-05 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
JP6442703B2 (ja) * | 2016-12-26 | 2018-12-26 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
JPWO2018124132A1 (ja) * | 2016-12-26 | 2018-12-27 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1741438A1 (en) | 2007-01-10 |
EP1741438A4 (en) | 2009-08-26 |
JP5041279B2 (ja) | 2012-10-03 |
US20080032384A1 (en) | 2008-02-07 |
JPWO2005102369A1 (ja) | 2008-03-06 |
CA2564180A1 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230233658A1 (en) | Formulation of a peptide vaccine | |
ES2199734T3 (es) | Vacuna con adyuvante de aceite. | |
US10213490B2 (en) | Compositions for providing agents that degrade in water | |
EP0781559B1 (en) | Oil adjuvant vaccine and method for preparing same | |
JP5041279B2 (ja) | 細菌細胞壁骨格成分を含有する製剤 | |
KR101365252B1 (ko) | 포스파티딜콜린 함유 주사용 조성물 및 이의 제조방법 | |
WO2006098241A1 (ja) | 難水溶性薬物を含有する医薬組成物 | |
JP2688235B2 (ja) | 医薬物質含有脂肪乳剤の用時調製型キットおよび医薬物質含有脂肪乳剤の調製方法 | |
CN103702662A (zh) | 控制释放肽制剂 | |
US11173197B2 (en) | Methods and compositions for nanoemulsion vaccine formulations | |
JPH06157294A (ja) | 脂肪微粒子製剤 | |
CN110430868A (zh) | 包含基于咪唑并喹啉的材料的纳米乳液及其用途 | |
JP4447779B2 (ja) | 細菌の菌体成分を有効成分とする癌免疫療法用製剤 | |
Bjerregaard et al. | Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin | |
JP7410883B2 (ja) | ワクチンアジュバントを含む製剤 | |
WO2012133554A1 (ja) | プロスタグランジン含有脂肪乳剤 | |
JP6664614B2 (ja) | Bcg−cwsの油性懸濁液製剤の製造方法 | |
JP2020002117A (ja) | スクアレン含有アジュバント組成物 | |
CN102125565B (zh) | 一种24-亚甲基环木菠萝醇阿魏酸酯的药物组合物 | |
CN111249451B (zh) | 一种糖脂类抗原注射液及其制备方法 | |
WO2010082092A1 (en) | Propofol based anesthetic with preservative | |
JP2017524036A (ja) | 薬物及び他の物質の送達のための経口組成物 | |
JPH02152931A (ja) | B型肝炎ワクチン | |
KR20070106988A (ko) | 백신용 약학적 조성물 | |
JP2004067536A (ja) | 乳化製剤の新規製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512563 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2564180 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11578859 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005734379 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005734379 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11578859 Country of ref document: US |